MarketCap
Facebook
X
TelegramAnnual report 2022
added 08-16-2022
Global Cord Blood Corporation Cost of Revenue 2011-2026 | CO
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Global Cord Blood Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 183 M | 179 M | 189 M | 186 M | 181 M | 143 M | - | - | - | 107 M | 86.7 M | 77.4 M |
All numbers in CNY currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 189 M | 77.4 M | 148 M |
Quarterly Cost of Revenue Global Cord Blood Corporation
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 46.2 M | - | - | - | 44.7 M | - | - | - | 48.3 M | - | - | - | 47.3 M | - | - | - | 45.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 27.4 M | 24.5 M | - | - | 27.1 M | 24.4 M | 23.3 M | 21.7 M | 21.8 M | 19.9 M | 20 M |
All numbers in CNY currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 48.3 M | 19.9 M | 31.6 M |
Cost of Revenue of other stocks in the Diagnostics research industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
608 M | - | -17.87 % | $ 25.9 M |  Canada |
|
Centogene N.V.
CNTG
|
162 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Accelerate Diagnostics
AXDX
|
9.45 M | - | -61.36 % | $ 2.46 M |  USA |
 |
Brainsway Ltd.
BWAY
|
6.6 M | $ 22.32 | -3.71 % | $ 99.4 M |  Israel |
 |
BioNano Genomics
BNGO
|
30.4 M | $ 1.45 | -3.67 % | $ 1.84 M | USA |
 |
Aspira Women's Health
AWH
|
3.86 M | - | -6.19 % | $ 10.5 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
144 M | $ 30.5 | -4.72 % | $ 328 M |  China |
 |
Biocept
BIOC
|
28.4 M | - | -13.05 % | $ 7.29 M | USA |
 |
Castle Biosciences
CSTL
|
60.2 M | $ 40.78 | 1.92 % | $ 1.13 B | USA |
 |
Co-Diagnostics
CODX
|
4.18 M | - | - | $ 79.8 M | USA |
 |
DexCom
DXCM
|
1.33 B | $ 70.44 | 1.29 % | $ 27.2 B | USA |
 |
Chembio Diagnostics
CEMI
|
38.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Genetic Technologies Limited
GENE
|
276 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
194 M | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
15 M | - | -11.32 % | $ 2.94 M | USA |
 |
Illumina
ILMN
|
1.51 B | $ 147.36 | 4.03 % | $ 23.4 B | USA |
 |
CareDx, Inc
CDNA
|
45.5 M | $ 20.08 | 0.35 % | $ 1.08 B | USA |
 |
Danaher Corporation
DHR
|
9.67 B | $ 234.95 | -0.44 % | $ 172 B | USA |
 |
DarioHealth Corp.
DRIO
|
14.4 M | $ 12.48 | 0.28 % | $ 354 M | Israel |
 |
Enzo Biochem
ENZ
|
17.3 M | - | -8.98 % | $ 14.8 K | USA |
 |
Fulgent Genetics
FLGT
|
176 M | $ 27.65 | -1.53 % | $ 836 M | USA |
 |
HTG Molecular Diagnostics
HTGM
|
4.57 M | - | -20.0 % | $ 1.06 M | USA |
 |
Exact Sciences Corporation
EXAS
|
221 M | $ 102.21 | -0.22 % | $ 18.9 B | USA |
 |
Lantheus Holdings
LNTH
|
546 M | $ 66.02 | 2.75 % | $ 4.57 B | USA |
 |
IQVIA Holdings
IQV
|
10 B | $ 234.18 | -1.47 % | $ 42.5 B | USA |
 |
QIAGEN N.V.
QGEN
|
801 M | - | - | $ 10.6 B |  Niderland |
 |
Heska Corporation
HSKA
|
146 M | - | - | $ 1.31 B | USA |
 |
Neogen Corporation
NEOG
|
473 M | $ 9.28 | 0.27 % | $ 2.01 B | USA |
 |
OPKO Health
OPK
|
495 M | $ 1.3 | 1.56 % | $ 902 M | USA |
 |
Pacific Biosciences of California
PACB
|
148 M | $ 2.36 | 6.79 % | $ 599 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
6.63 B | $ 188.87 | -0.33 % | $ 21 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
9.38 B | $ 272.02 | 0.42 % | $ 22.8 B | USA |
 |
ICON Public Limited Company
ICLR
|
3.97 B | $ 176.57 | -3.31 % | $ 14.6 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
1.52 B | $ 688.67 | -3.73 % | $ 56.8 B | USA |
 |
Myriad Genetics
MYGN
|
252 M | $ 5.65 | -4.56 % | $ 512 M | USA |
 |
ENDRA Life Sciences
NDRA
|
173 K | $ 4.67 | -2.3 % | $ 2.51 M | USA |
 |
Agilent Technologies
A
|
2.91 B | $ 135.52 | -2.95 % | $ 41.2 B | USA |